BioNTech to Close Multiple Production Sites and Cut Up to 1,860 Jobs

BioNTech plans to close several production facilities in Germany and Singapore by 2027 to reduce costs and address overcapacity. The restructuring aims to save approximately 500 million euros annually to fund cancer research and development.

Key points

• Affected sites include facilities in Idar-Oberstein, Marburg, Tübingen, and Singapore.
• The company reported a net loss of 531.9 million euros in the first quarter of 2026, driven by lower COVID-19 vaccine sales and high R&D costs.
• BioNTech founders Uğur Şahin and Özlem Türeci are set to step down from their board positions by the end of 2026.
• The company intends to sell the impacted sites, either partially or completely, to prevent total closure.
• Labor representatives and the IG BCE union have strongly criticized the planned job cuts.

Why it matters

This restructuring reflects the pharmaceutical industry's shift away from pandemic-era production levels toward long-term investment in oncology, impacting thousands of jobs and regional manufacturing capacity.